Purchase this article with an account.
P. Stergiou, D. Kokkinou, K. Malamos, A. Felekidis, S. Kailari; Varying Doses of Intravitreal Bevacizumab (Avastin) for the Treatment of Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1395. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To test the varying doses of intravitreal bevacizumab in patients with retinal neovascularization (NVE or NVD) secondary to diabetes mellitus in a interventional, consecutive, retrospective case series. The study was conducted in compliance with the Declaration of Helsinki.
Twenty eyes of 19 patients with retinal neovascularization due to Proliferative Diabetic Retinopathy. Patients were divided in four groups received intravitreal bevacizumab (150 µg -1.25 mg). First group received 1.25 mg, second group 600 µg, third group 300 µg and fourth group 150 µg in a single intravitreal injection under sterile conditions. Ophthalmic evaluations included non-standardized Snellen visual acuity (VA), complete ophthalmic examination, optical coherence tomography and mostly fluorescein angiography to identify the presence of NVE or NVD and the amount of leakage.
No significant ocular or systemic adverse effects were noted. Complete resolution of angiographic leakage of neovascularization was noted in all eyes from the first week.
Short-term results suggest that intravitreal bevacizumab even in lower doses than standard is effective in reversing temporarily NVE or NVD in diabetics.
This PDF is available to Subscribers Only